CIPH Ciphergen Biosystems (MM)

Ciphergen Names Executive to Head New Clinical Diagnostics Division FREMONT, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced today that Gail Page will join Ciphergen as President of its newly formed Diagnostics Division; she will also become an Executive Vice President of Ciphergen Biosystems, Inc. In her new position, Ms. Page will lead a major clinical diagnostics business initiative by the company to develop and commercialize Protein Molecular Diagnostics, based on the ProteinChip(R) platform. Ms. Page will report to William E. Rich, President and CEO of Ciphergen. "We are delighted that Gail is joining Ciphergen to lead our Protein Molecular Diagnostics commercialization effort," stated William E. Rich, President and CEO of Ciphergen Biosystems. "She has over 25 years of experience and a deep understanding of all aspects of the diagnostics industry, which is precisely what we need at this time to convert our many exciting biomarker discovery programs into commercially viable diagnostic tests." Gail has a 25 year career in the diagnostics industry, covering all of the critical functions ranging from senior management to sales/marketing and business development, technology assessment and acquisitions, as well as operations. From October 2000 to January 2003, Ms. Page was the Executive Vice President and Chief Operating Officer of Luminex Corporation. From 1988 to 2000, Ms. Page held various senior level management positions with Laboratory Corporation of America. In 1993, she was named Senior Vice President, Office of Science and Technology at LabCorp, responsible for the management of scientific affairs in addition to the diagnostics business segment. Additionally, from 1995 to 1997, Ms. Page headed the Cytology and Pathology Services business unit for LabCorp. From 1988 to 2000, she was a member of the Scientific Advisory Board and chaired the committee from 1993 to 1997. Prior to her years at LabCorp and its predecessor Roche Biomedical, Gail worked in various functions in the academic and diagnostic industry. She received her Medical Technology degree in 1976 from the University of Florida in combination with an AS degree in Cardiopulmonary Technology. Ms. Page commented: "I'm excited to be joining Ciphergen as I believe that Ciphergen's ProteinChip technology has the potential to make a major impact on the diagnostics industry through the discovery and development of multi-biomarker assays. Ciphergen has the content required to offer a breakthrough in Protein Molecular Diagnostic testing for early disease diagnosis and prognosis and therapeutic decision-making, especially in cancer." Beginning in 2000, Ciphergen established the first of a series of Biomarker Discovery Centers(R) and established a major collaboration with Johns Hopkins Medical School with the intention of employing Ciphergen technology to discover biomarkers and develop assays based on panels of biomarkers which might have greater predictive power than single marker tests. While Ciphergen is perhaps best noted for its diagnostic efforts in the early detection in cancer, the company also has active discovery programs underway in neurology, cardiovascular and infectious disease, focused on a variety of clinical questions including disease treatment response, monitoring, classification and prognosis. Further details regarding Ciphergen's Diagnostics Division and business plans are expected to be announced in the coming months. About Ciphergen Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research, diagnostic and process proteomics applications, as well as a broad range of bioseparations media for protein purification. ProteinChip Systems enable protein discovery, profiling, characterization, identification and assay development to provide researchers with predictive diagnostic capabilities and a better understanding of biological functions at the protein level. Ciphergen's Diagnostic Division is dedicated to the discovery of protein biomarkers and panels of biomarkers that may be developed into diagnostic assays that improve patient care and to providing collaborative services through Biomarker Discovery Centers that lead to improved drug toxicity, efficacy and theranostic assays. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the use of ProteinChip technology to discover useful protein biomarkers, develop and commercialize protein molecular diagnostics that improve patient care, the ability to provide services that lead to improve toxicology assays and diagnostic assays, and statements regarding our Diagnostics Division. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the ProteinChip technology's ability to validate and/or develop these protein biomarkers as diagnostic or toxicology assays, and the Company's ability to successfully commercialize such tests. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated November 14, 2003, for further information regarding these and the other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue Carruthers, Investor Relations of Ciphergen Biosystems, Inc., +1-510-505 2297 Web site: http://www.ciphergen.com/

Copyright